InvestorsObserver
×
News Home

Is it Time to Dump Equillium Inc (EQ) Stock After it Has Risen 21.93% in a Week?

Thursday, February 04, 2021 10:07 AM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump Equillium Inc (EQ) Stock After it Has Risen 21.93% in a Week?

Equillium Inc (EQ) stock has gained 21.93% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bullish
Equillium Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on EQ!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With EQ Stock Today?

Equillium Inc (EQ) stock is trading at $7.45 as of 10:05 AM on Thursday, Feb 4, a rise of $0.83, or 12.54% from the previous closing price of $6.62. The stock has traded between $7.17 and $8.45 so far today. Volume today is low. So far 481,581 shares have traded compared to average volume of 918,529 shares.

To screen for more stocks like Equillium Inc click here.

More About Equillium Inc

Equillium Inc is a biopharmaceutical company. It is developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Its primary product candidate is itolizumab, which targets the CD6-ALCAM signaling pathway, which helps in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab is the treatment for multiple severe immuno-inflammatory disorders, including graft versus host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.

Click Here to get the full Stock Score Report on Equillium Inc (EQ) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App